The global market for GLP-1 receptor agonists shows a surge in demand due to their efficacy in managing type 2 diabetes. Several biotechnological companies have earned FDA approval to produce these life-changing medications. {Novo Nordisk|Ascensia Pharmaremains a leading developer of GLP-1 receptor agonists, with proven products like Rybelsus.